Abrogation of wild-type p53-mediated transactivation is insufficient for mutant p53-induced immortalization of normal human mammary epithelial cells.

The p53 protein has become a subject of intense interest since the discovery that about 50% of human cancers carry p53 mutations. Mutations in the p53 gene are the most frequent genetic lesions in breast cancer, suggesting a critical role for p53 protein in normal mammary epithelial cell (MEC) growth control. We previously demonstrated that abrogation of the p53 function by a cancer-derived p53 mutant, del239, was sufficient to induce immortalization of normal MECs. To further extend these findings and to examine the mechanism of mutant p53-induced immortalization of MECs, we tested the immortalizing ability of four selected p53 mutants (R175H, R248W, R249S, and R273H), which involve residues that cluster close to N239 in the three-dimensional structure and which are critical for the DNA-binding function of p53. Interestingly, two of these mutants (R175H and R249S) reproducibly immortalized 76N normal MECs, whereas the other two mutants (R248W and R273H) induced an extension of life span but not immortalization. These results further substantiate that selective ablation of p53 function with dominant-negative mutants is sufficient for immortalization of MECs. To determine whether abrogation of the transactivation function of endogenous p53 was important for the differential immortalizing ability of p53 mutants, we measured the effects of mutant p53 on the endogenous wild-type p53-mediated transactivation of a chloramphenicol acetyltransferase reporter linked to a consensus p53 binding DNA sequence in transiently transfected 76N MECs. All of the mutants, regardless of their immortalizing phenotype, abrogated the endogenous wild-type p53-mediated transactivation to a similar extent. Thus, abrogation of transactivation function is not sufficient for mutant p53-induced immortalization of normal MECs. The p53-immortalized MECs showed substantial telomerase activity; however, induction of telomerase activity occurred at late passages and was undetectable in mutant p53-expressing cells prior to immortalization. We suggest that mechanisms other than abrogation of transactivation and induction of telomerase activity determine the differential MEC-immortalizing behavior of various p53 mutants.

[1]  Amanda G Paulovich,et al.  When Checkpoints Fail , 1997, Cell.

[2]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[3]  A. Levine,et al.  Wild-type p53 negatively regulates the expression of a microtubule-associated protein. , 1996, Genes & development.

[4]  D. Wazer,et al.  Mutant p53-induced immortalization of primary human mammary epithelial cells. , 1996, Cancer research.

[5]  E. Androphy,et al.  Mutational analysis of human papillomavirus type 16 E6 demonstrates that p53 degradation is necessary for immortalization of mammary epithelial cells , 1996, Journal of virology.

[6]  S. Velasco-Miguel,et al.  Induction of the growth inhibitor IGF-binding protein 3 by p53 , 1995, Nature.

[7]  A. Levine,et al.  Two critical hydrophobic amino acids in the N-terminal domain of the p53 protein are required for the gain of function phenotypes of human p53 mutants. , 1995, Oncogene.

[8]  C. Harris,et al.  Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent. , 1995, Oncogene.

[9]  D. Wazer,et al.  Immortalization of distinct human mammary epithelial cell types by human papilloma virus 16 E6 or E7. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[10]  J. Shay,et al.  Detection of telomerase activity in human cells and tumors by a telomeric repeat amplification protocol (TRAP) , 1995 .

[11]  L. Gollahon,et al.  Spontaneous in vitro immortalization of breast epithelial cells from a patient with Li-Fraumeni syndrome , 1995, Molecular and cellular biology.

[12]  D. Beach,et al.  Cyclin G is a transcriptional target of the p53 tumor suppressor protein. , 1994, The EMBO journal.

[13]  P. Jeffrey,et al.  Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. , 1994, Science.

[14]  S. Kern.  p53: tumor suppression through control of the cell cycle. , 1994, Gastroenterology.

[15]  D. Wazer,et al.  Loss of p53 protein during radiation transformation of primary human mammary epithelial cells. , 1994, Molecular and cellular biology.

[16]  J. Y. Chen,et al.  Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences. , 1993, Oncogene.

[17]  J. Pipas,et al.  Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53 , 1993, Nature.

[18]  M. Gould,et al.  Increased expression of specific protein tyrosine phosphatases in human breast epithelial cells neoplastically transformed by the neu oncogene. , 1993, Cancer research.

[19]  E. Androphy,et al.  Enhanced degradation of p53 protein in HPV‐6 and BPV‐1 E6‐immortalized human mammary epithelial cells. , 1993, The EMBO journal.

[20]  A. Levine,et al.  Gain of function mutations in p53 , 1993, Nature Genetics.

[21]  M. Abeloff,et al.  Management of locally recurrent breast cancer , 1993, Cancer.

[22]  B. Vogelstein,et al.  A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia , 1992, Cell.

[23]  M. Kastan,et al.  Wild-type p53 is a cell cycle checkpoint determinant following irradiation. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[24]  C. Redmond,et al.  Ipsilateral breast tumor recurrence and survival following lumpectomy and irradiation: pathological findings from NSABP protocol B-06. , 1992, Seminars in surgical oncology.

[25]  B. Vogelstein,et al.  Participation of p53 protein in the cellular response to DNA damage. , 1991, Cancer research.

[26]  V. Band,et al.  Loss of p53 protein in human papillomavirus type 16 E6-immortalized human mammary epithelial cells , 1991, Journal of virology.

[27]  K. Vousden,et al.  Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation , 1991, Cell.

[28]  M. Kraus,et al.  Oncogenic potential of erbB-2 in human mammary epithelial cells. , 1991, Oncogene.

[29]  J. Milner,et al.  Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation , 1991, Cell.

[30]  E. Appella,et al.  Growth suppression induced by wild-type p53 protein is accompanied by selective down-regulation of proliferating-cell nuclear antigen expression. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Arnold J. Levine,et al.  The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53 , 1990, Cell.

[32]  B. Vogelstein,et al.  Suppression of human colorectal carcinoma cell growth by wild-type p53. , 1990, Science.

[33]  V. Band,et al.  Distinctive traits of normal and tumor-derived human mammary epithelial cells expressed in a medium that supports long-term growth of both cell types. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[34]  F. McCormick,et al.  Transformation of human mammary epithelial cells by oncogenic retroviruses. , 1988, Cancer research.

[35]  M. Stampfer,et al.  Induction of transformation and continuous cell lines from normal human mammary epithelial cells after exposure to benzo[a]pyrene. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[36]  S. L. Hammond,et al.  Serum-free growth of human mammary epithelial cells: rapid clonal growth in defined medium and extended serial passage with pituitary extract. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[37]  J. Shay,et al.  Telomerase activity in human cancer. , 1996, Current opinion in oncology.

[38]  H. Hausen,et al.  Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. , 1994, Current topics in microbiology and immunology.

[39]  H. zur Hausen.  Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. , 1994, Current topics in microbiology and immunology.

[40]  G. Thomas,et al.  Short direct repeats flanking deletions, and duplicating insertions in p53 gene in human cancers. , 1993, Oncogene.